• Applied ddhCTP: Protocols & Pitfalls in Antiviral Assays

  2026-07-07

  ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) is transforming RNA virus research by enabling precise, direct inhibition of viral RNA synthesis in cellular and in vitro systems. This guide details how to leverage APExBIO’s ddhCTP for robust, reproducible results in antiviral workflows, highlighting troubleshooting tactics and experimental optimizations.

• Deracoxib and Piroxicam Reduce Canine Osteosarcoma Cell Viab

  2026-07-06

  This study evaluates the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cell lines, establishing that both NSAIDs decrease tumor cell viability at high concentrations without inducing apoptosis. The findings inform research strategies in antiproliferative agent screening and highlight the need for targeted therapies that spare normal cells.

• Ibrutinib (PCI-32765): Pushing the Boundaries of Preclinical

  2026-07-06

  Explore how Ibrutinib (PCI-32765) redefines B-cell receptor signaling inhibition in chronic lymphocytic leukemia and autoimmune research. This article uncovers advanced applications, underlying mechanisms, and practical assay insights not covered elsewhere.

• Transmission Dynamics of Carbapenemase Genes in CREC: 2022–2

  2026-07-05

  This study provides a detailed molecular and epidemiological characterization of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. The findings reveal high rates of multidrug resistance and successful gene transfer, emphasizing the urgent need for robust surveillance and targeted research protocols.

• Repurposing Vitamins as SARS-CoV-2 Inhibitors: Docking Insig

  2026-07-04

  This study explores the repurposing of common vitamins as inhibitors of SARS-CoV-2 replication and entry, using in silico molecular docking and dynamics focused on the viral 3CL protease and spike receptor-binding domain. The findings highlight the potential of safe, widely available compounds to disrupt key stages of coronavirus infection, informing new directions in antiviral therapeutics research.

• Caspase-3 Cleavage of NDUFS1 Drives Trichothecene-Induced RO

  2026-07-03

  This study elucidates how trichothecene mycotoxins, such as DON and T-2 toxin, induce hepatic oxidative stress by activating caspase-3, which cleaves mitochondrial NDUFS1 and disrupts electron transport, amplifying ROS production. The findings reveal a feedback loop between mitochondrial and ER-derived ROS, providing mechanistic insight into trichothecene-induced hepatotoxicity and identifying potential intervention targets.

• Platanoside Prevents Ferroptosis in ALI via Keap1/Nrf2/GPX4

  2026-07-03

  This study demonstrates that platanoside, a natural flavonoid glycoside, protects against acute lung injury (ALI) by promoting autophagic degradation of Keap1, thereby activating the Nrf2/GPX4 antioxidant pathway and inhibiting ferroptosis. These findings highlight a novel, multi-targeted approach to mitigating oxidative stress and cellular damage in ALI, with implications for research on regulated cell death in inflammatory diseases.

• Scalable Production of EPSC-iMSC Extracellular Vesicles for

  2026-07-02

  Gong et al. present a robust bioreactor-based platform for generating extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs). This innovation addresses longstanding bottlenecks in EV therapy manufacturing, enabling consistent, high-yield EV production suitable for translational pulmonary fibrosis research and beyond.

• MVC Triggers RhoA/ROCK1 Pathway to Disrupt Tight Junctions

  2026-07-02

  Ren et al. (2025) provide direct evidence that Minute Virus of Canines (MVC) activates the RhoA/ROCK1/MLC2 signaling cascade to dismantle epithelial tight junctions, exposing occludin and facilitating viral entry. Their mechanistic insights establish new targets for antiviral intervention and clarify the molecular pathogenesis of MVC infection.

• Intermediate Pluripotent Stem Cells Enable Direct Germ Cell

  2026-07-01

  Yu et al. present a robust method for deriving intermediate pluripotent stem cells (FTW-PSCs) that model the formative state of the mammalian epiblast. This innovation expands the in vitro toolkit for studying early development and germ cell specification, with direct implications for stem cell biology and regenerative research.

• Partial BACE1 Inhibition Reduces Amyloid-β Without Synaptic

  2026-07-01

  Satir et al. (2020) demonstrated that partial inhibition of BACE1, yielding up to a 50% reduction in amyloid-β secretion, does not impair synaptic transmission in cultured neurons. This finding suggests a feasible therapeutic window for BACE1 inhibitors in Alzheimer's disease research, balancing amyloid reduction and preservation of synaptic function.

• Erastin: Precision Ferroptosis Inducer for Applied Cancer Re

  2026-06-30

  Erastin sets the gold standard for dissecting ferroptosis in RAS- or BRAF-mutant tumor lines, enabling reproducible oxidative stress assays and pathway deconvolution. This guide delivers actionable protocols, troubleshooting tips, and real-world insights—empowering researchers to exploit Erastin’s selective ferroptosis induction with confidence.

• H-89 and the cAMP-PKA Axis: Strategic Leverage in Bone Biolo

  2026-06-30

  This thought-leadership article explores how the selective cAMP-dependent protein kinase inhibitor H-89 empowers translational researchers to dissect the intricate cAMP-PKA axis—now recognized as a critical modulator of Wnt-induced O-GlcNAcylation and aerobic glycolysis in bone formation. Drawing from the latest mechanistic insights, we offer actionable guidance for experimental design, discuss real-world protocol strategies, and situate H-89 within the competitive landscape of kinase inhibitors. The piece bridges novel evidence with translational potential, aiming to advance both fundamental discovery and clinical applications in osteogenesis.

• Targeting Lysosomal Exocytosis in Cartilage Disease: Vacuoli

  2026-06-29

  This article reframes lysosomal exocytosis from a basic cell biology process to a pivotal driver of cartilage pathology in lysosomal storage disorders, particularly mucopolysaccharidosis type IVA (MPS IVA). It delivers mechanistic insight, strategic experimental guidance, and a forward-looking perspective for translational researchers, highlighting Vacuolin-1’s unique role as a selective inhibitor and research enabler.

• Butylated Hydroxyanisole (BHA): Optimizing ROS & Stress Assa

  2026-06-29

  Butylated hydroxyanisole (BHA) delivers robust and reproducible antioxidant control for oxidative stress and ROS detection workflows. Learn how APExBIO’s BHA empowers advanced apoptosis, inflammation, and redox biology assays through protocol-driven enhancements and troubleshooting strategies.

13006 records 1/868 page Next 12345 下5页 Last page